Although mutations of the BRAF gene in HNSCC are rare [15], a phase II window-of-opportunity trial demonstrated a significant reduction in RAS/MEK/ERK pathway activation, along with notable clinical and metabolic tumor responses to trametinib in patients with oral cavity HNSCC [16]. This evidence concerns the gene MAPK1 and head and neck squamous cell carcinoma.